ライフサイエンスコーパス: gonorrhea

1 (such as multiple sex partners and previous gonorrhea).

2 infected adults for syphilis, chlamydia, and gonorrhea.

3 eisseria gonorrhoeae, the causative agent of gonorrhea.

4 al agent of the sexually transmitted disease gonorrhea.

5 ased regimens in the treatment of pharyngeal gonorrhea.

6 treatment failures among MSM diagnosed with gonorrhea.

7 bsence of immunologic memory elicited during gonorrhea.

8 ctam antibiotics as effective treatments for gonorrhea.

9 ossibility that an LOS vaccine might prevent gonorrhea.

10 es the common sexually transmitted infection gonorrhea.

11 ae is an obligate human pathogen that causes gonorrhea.

12 not be used for the detection of pharyngeal gonorrhea.

13 t they are associated with a reduced risk of gonorrhea.

14 eisseria gonorrhoeae, the causative agent of gonorrhea.

15 iscuss the development of new treatments for gonorrhea.

16 s crucial to ensure appropriate treatment of gonorrhea.

17 hese 63 women, only 8 (13%) had chlamydia or gonorrhea.

18 presence of coinfections with chlamydia and gonorrhea.

19 hogen and the causative agent of the disease gonorrhea.

20 otic resistance limits treatment options for gonorrhea.

21 were tested for trichomonas, chlamydia, and gonorrhea.

22 for chlamydia when patients are treated for gonorrhea.

23 producing lactobacilli protect women against gonorrhea.

24 % reported symptoms versus 40% of those with gonorrhea.

25 ed to choose effective empiric therapies for gonorrhea.

26 least annually for syphilis, chlamydia, and gonorrhea.

27 tegies to limit the spread of drug-resistant gonorrhea.

28 ures to respond to the threat of untreatable gonorrhea.

29 ants associated with anorectal chlamydia and gonorrhea.

30 onitor at-risk individuals for chlamydia and gonorrhea.

31 on should be screened for both chlamydia and gonorrhea.

32 ollowing treatment for pharyngeal and rectal gonorrhea.

33 and 1000 mg) for treatment of uncomplicated gonorrhea.

34 nical trials for treatment of drug-resistant gonorrhea.

35 , herpes simplex virus type 2 detection, and gonorrhea.

36 exually-transmitted diseases (STDs), such as gonorrhea.

37 s test is unsuitable as a screening tool for gonorrhea.

38 nge of ailments such as edema, jaundice, and gonorrhea.

39 ls for treatment of patients with urogenital gonorrhea.

40 innate effectors is a fascinating aspect of gonorrhea.

41 highly effective for treatment of urogenital gonorrhea.

42 cies, N. gonorrhoeae, the etiologic agent of gonorrhea.

43 d maintaining infection in a murine model of gonorrhea.

44 Y), active syphilis (4.01 cases/100 PY), and gonorrhea (1.78 cases/100 PY) was higher among women tha

45 nty-eight patients had single infections (15 gonorrhea, 10 chlamydial infection, 3 trichomoniasis), a

46 t or recurrent infection among patients with gonorrhea (3 percent vs. 11 percent, P=0.01) than in tho

47 Standard wet vaginal swab PCR detected more gonorrhea (3.3%) than routine cervical culture (2.1%).

48 cident infection: chlamydia, 18%; HSV-2, 4%; gonorrhea, 4%; and trichomoniasis, 3%.

49 ); syphilis, 9 (6%); genital herpes, 8 (6%); gonorrhea, 5 (4%); chlamydia, 5 (4%); genital warts, 2 (

50 By using LCR to diagnose gonorrhea, 54 (17.5%) of 309 patients had positive tests

51 year; 95% CI, 2.9%-21.1%), and those who had gonorrhea (6.7%/year; 95% CI, 1.5%-20.3%).

52 %; herpes simplex virus type 2 (HSV-2), 14%; gonorrhea, 6%; trichomoniasis, 3%; and hepatitis B, 2%.

53 tion of repeat positive tests for pharyngeal gonorrhea 7-180 days following treatment among persons r

54 iasis in 23 (18%); genital herpes, 20 (12%); gonorrhea, 9 (7%); syphilis, 7 (6%); genital warts, 7 (6

55 cept of a novel therapeutic approach against gonorrhea, a disease rapidly becoming resistant to conve

56 sseria gonorrhoeae is the causative agent of gonorrhea, a disease that is restricted to humans.

57 ria gonorrhoeae is the bacterium that causes gonorrhea, a major sexually transmitted disease and a si

58 Gonorrhea, a sexually transmitted disease caused by Neis

59 Neisseria gonorrhoeae causes gonorrhea, a sexually transmitted infection characterize

60 Gonorrhea (adjusted hazard ratio [HR], 3.09 [95% CI, 1.4

61 History of gonorrhea (adjusted odds ratio = 1.76, 95% confidence in

62 5% confidence interval {CI}, 1.38-2.97]) and gonorrhea (adjusted RR, 1.66 [95% CI, 1.07-2.60]) were a

63 lts confirmed a relatively low prevalence of gonorrhea among symptomatic men (12%) and chlamydia amon

64 Gonorrhea, an obligate human infection, is on the rise w

65 oviding insight into the host restriction of gonorrhea and addressing why Por1B strains, but not Por1

66 sociated with a lower reduction in prevalent gonorrhea and chlamydia (24% vs. 25%; adjusted prevalenc

67 ed with a significant reduction in prevalent gonorrhea and chlamydia (30% vs. 43%; adjusted prevalenc

68 m use in the previous 3 months and prevalent gonorrhea and chlamydia (Gc/Ct) was compared between par

69 completing the questionnaire were tested for gonorrhea and chlamydia at this time and also 3 months e

70 lification tests are accurate for diagnosing gonorrhea and chlamydia in asymptomatic persons.

71 revious research has supported screening for gonorrhea and chlamydia in asymptomatic, sexually active

72 Associations between condom use and incident gonorrhea and chlamydia infection were compared between

73 l lesions, tested endocervical specimens for gonorrhea and chlamydia infection with DNA probes, teste

74 23 and 22 LHJs provided data on gonorrhea and chlamydia outcomes, respectively.

75 n, increases partner treatment and decreases gonorrhea and chlamydia reinfection rates.

76 eased protection from condom use and reduced gonorrhea and chlamydia risk (p(trend) = 0.032).

77 cer with a Papanicolaou smear, screening for gonorrhea and chlamydia).

78 sexually transmitted diseases (STDs) such as gonorrhea and chlamydia, a similar technique for trichom

79 specificity of 97% or greater for diagnosing gonorrhea and chlamydia, regardless of specimen type or

80 al human papillomavirus infection, tests for gonorrhea and chlamydia, wet mounts, and serologic assay

81 enty-one (16.2%) were infected with incident gonorrhea and chlamydia, with no infections among consis

82 er there were core groups of transmitters of gonorrhea and chlamydial infection among 14- to 35-year-

83 93, sociodemographic risk factors for repeat gonorrhea and chlamydial infection were examined.

84 ulations influence the endemic prevalence of gonorrhea and herpes simplex virus type 2 infection.

85 y important sexually transmitted infections, gonorrhea and HIV.

86 re tested, for both chlamydial infection and gonorrhea and in both men and women.

87 the development of better animal models for gonorrhea and may also have implications in the choice o

88 tion and ciliated cell death associated with gonorrhea and pelvic inflammatory disease.

89 hat cause the sexually transmitted infection gonorrhea and serious bacterial meningitis and septicemi

90 y of antibiotic usage and resistance against gonorrhea and the consequences of resistance mechanisms

91 ent of effective prophylactic agents against gonorrhea and the study of adaptation by Neisseria gonor

92 The incidence of gonorrhea and/or chlamydia was 19.1 per 100 person-years

93 ronidazole did not decrease the incidence of gonorrhea and/or chlamydia.

94 The primary outcome was the incidence of gonorrhea and/or chlamydia.

95 tamine H2-receptor antagonists, splenectomy, gonorrhea, and body mass index.

96 n for conditions other than cervical cancer, gonorrhea, and chlamydia, for which the USPSTF has alrea

97 cancer or condition except cervical cancer, gonorrhea, and chlamydia, which are covered by other USP

98 nt interviews and testing for HIV, syphilis, gonorrhea, and chlamydia.

99 were very amenable to home screening for BV, gonorrhea, and chlamydia.

100 s in the incidence of syphilis among adults, gonorrhea, and congenital syphilis over 11 years in Chin

101 athogens, including measles virus, Neisseria gonorrhea, and human herpesvirus 6, have been described,

102 sex partners, prior diagnosis of syphilis or gonorrhea, and lack of HSV-1 antibody.

103 t cause diseases such as cholera, pneumonia, gonorrhea, and meningitis.

104 les virus, Streptococcus pyogenes, Neisseria gonorrhea, and Neisseria meningitidis.

105 pened trend was observed in the incidence of gonorrhea, and no trend was observed for the incidence o

106 nts treated with specific antimicrobials for gonorrhea, and trends of these measures over time.

107 6 years was tested for chlamydial infection, gonorrhea, and trichomoniasis in wave 3 (2001-2002) of t

108 t of participants were tested for chlamydia, gonorrhea, and trichomoniasis.

109 to reduce a woman's risk of acquiring HIV-1, gonorrhea, and trichomoniasis.

110 uisition of human immunodeficiency virus and gonorrhea, and women who are colonized with H(2)O(2)-pro

111 Maternal gonorrhea (aOR, 19.5; 95% CI, 2.5-151.3) and higher mate

112 ally representative surveys of chlamydia and gonorrhea are an important measure of disease burden and

113 as, reinforcing the inference that risks for gonorrhea are associated with definable sociogeographic

114 Safe and effective vaccines against gonorrhea are needed urgently.

115 Additional treatment options for gonorrhea are needed.

116 erminants of risk for STI acquisition, using gonorrhea as an index infection.

117 n appropriate control strategy for anorectal gonorrhea, as few infections would be missed.

118 0% effective for treatment of culture-proven gonorrhea at genital, oral, and rectal sites of infectio

119 isolates from all consecutive patients with gonorrhea attending the Genitourinary Medicine clinic in

120 inical trials for treatment of uncomplicated gonorrhea based on a variety of beneficial attributes in

121 to be male and female core transmitters for gonorrhea but there may not be core transmitters for chl

122 ve agent of the sexually transmitted disease gonorrhea, can be studied using experimental infection o

123 (gonococci [GC]), the etiological agents for gonorrhea, can cause repeated infections.

124 Of the 6,108 gonorrhea cases analyzed, 9% were repeaters.

125 icant geographic clusters of high prevalence gonorrhea cases can be located after controlling for rac

126 In the GIS system, gonorrhea cases were geocoded by reported address using

127 Of all anorectal chlamydia/gonorrhea cases, 72% (n = 92)/33% (n = 4) were diagnosed

128 smaller distances than did singly occurring gonorrhea cases.

129 ally similar to those in nationally reported gonorrhea cases.

130 During 1995-1997, an outbreak of 66 cases of gonorrhea caused by an erythromycin-resistant (Ery(r); M

131 transmitted infections (STIs; eg, syphilis, gonorrhea, chlamydia) each year, with commercial sex int

132 In 924 FSWs, the prevalence of HIV, gonorrhea, chlamydia, and syphilis titers > or =1:8 was

133 ct after sexual assault; empiric therapy for gonorrhea, chlamydia, and trichomoniasis based on update

134 reviews the new STD treatment guidelines for gonorrhea, chlamydia, bacterial vaginosis, trichomonas,

135 .05 for each), and were more likely to have gonorrhea, chlamydia, or pelvic inflammatory disease.

136 r analysis of 228 follow-up visits ending in gonorrhea/chlamydia ("case intervals") and 743 self-matc

137 self-matched follow-up visits not ending in gonorrhea/chlamydia ("noncase intervals") (183 women), c

138 rom 32 HIV-negative STD clinic patients with gonorrhea, chlamydial infection, or trichomoniasis were

139 re, thus potentially improving chlamydia and gonorrhea control efforts.

140 ntial component of an integrated approach to gonorrhea control.

141 crobial classes challenges this component of gonorrhea control.

142 e and LCR-positive specimens, a diagnosis of gonorrhea could be confirmed for 52 of 54 patients with

143 ts took their own vaginal swab specimens for gonorrhea culture and LCR testing.

144 oportion of men treated with penicillins for gonorrhea declined from 39.5% in 1988 to 0% in 1994, whi

145 mselves was significantly more sensitive for gonorrhea diagnosis of women than cervical LCR or cultur

146 otential to simplify specimen collection for gonorrhea diagnosis.

147 Pharyngeal and rectal gonorrhea DNA persisted in 8% of men 14 days after treat

148 For rectal gonorrhea, DNA positivity was present in 6% (95% CI, 1.4

149 The mucosal Ig response apparent during gonorrhea does not correlate with that observed systemic

150 alysis of patients diagnosed with pharyngeal gonorrhea during 1993-2011, at a sexually transmitted di

151 cause of the sexually transmitted infection gonorrhea, elicits low levels of specific Ig that declin

152 rhoeae, the Gram-negative etiologic agent of gonorrhea, facilitate colonization of the human host.

153 infection, and to co-treat individuals with gonorrhea for chlamydia.

154 mune response in male subjects infected with gonorrhea for the first time.

155 ed Thayer-Martin medium for the diagnosis of gonorrhea from endocervical specimens.

156 tive urinalysis biosensor to monitor UTI and gonorrhea from human urine.

157 action may contribute to the transmission of gonorrhea from infected males to their sexual partners.

158 Gonorrhea (GC) and chlamydia (CT) are the most commonly

159 or simultaneous detection of chlamydia (CT), gonorrhea (GC), and trichomonas (TV).

160 Treatment for gonorrhea has been complicated by antimicrobial resistan

161 candidate microbicides for the prevention of gonorrhea has been seriously hindered by the lack of an

162 erculosis, malaria, Staphylococcus aureus or gonorrhea has led to rapidly increasing population level

163 agent of the sexually transmitted infection, gonorrhea, has developed resistance to most conventional

164 2.8; 95% confidence interval [CI], 2.0-3.9), gonorrhea (HR, 1.6; 95% CI, 1.1-2.2), and vulvovaginal c

165 ; 95% confidence interval [CI], 1.2-3.5) and gonorrhea (HR, 1.7; 95% CI, 1.1-2.6), after controlling

166 Risk factors for gonorrhea identified among STD clinic patients formed a

167 This clonal outbreak of gonorrhea illustrates the ongoing need for behavioral pr

168 than culture for the detection of pharyngeal gonorrhea in at-risk patients.

169 m to evaluate the geographic epidemiology of gonorrhea in Baltimore, Maryland, during 1994.

170 distribution of repeat and singly occurring gonorrhea in Baltimore, Maryland, was examined to identi

171 Results for gonorrhea in females demonstrated sensitivities for endo

172 -identified race (STC-2), and local rates of gonorrhea in men (STC-3).

173 ended screening guidelines for chlamydia and gonorrhea in men and women in the United States?

174 its and harms of screening for chlamydia and gonorrhea in men.

175 Despite a declining incidence of gonorrhea in much of the industrialized world, antimicro

176 The USPSTF recommends screening for gonorrhea in sexually active females aged 24 years or yo

177 Additional factors associated with gonorrhea in the general population included secondary e

178 who were tested for syphilis, chlamydia, and gonorrhea in the past 12 months by year and stratified b

179 help develop a more complete epidemiology of gonorrhea in the United States.

180 t fully reflect trends for all patients with gonorrhea in the United States.

181 To study the pathogenesis of gonorrhea in this cell type, we have developed a method

182 low to recommend its routine use to test for gonorrhea in urine specimens.

183 Acute gonorrhea in women is characterized by a mucopurulent ex

184 sentinel clinics, and incidence of reported gonorrhea in women, both measured at the community level

185 k between biofilm formation and asymptomatic gonorrhea in women.

186 Chlamydia test positivity and gonorrhea incidence in women decreased over the study pe

187 e and decrease chlamydia test positivity and gonorrhea incidence in women.

188 ce ratio = 0.89, 95% CI 0.77-1.04, p = 0.15; gonorrhea incidence rate ratio = 0.91, 95% CI .71-1.16,

189 % reduction in both chlamydia positivity and gonorrhea incidence, though the confidence bounds on the

190 ts at STD clinics who received treatment for gonorrhea, including sex partners of gonorrhea-infected

191 sets of selective testing criteria (STC) for gonorrhea, incorporating risk factors identified using l

192 Overall testing for chlamydia and gonorrhea increased from 22% to 42% (PTREND < .01), and

193 ent for gonorrhea, including sex partners of gonorrhea-infected patients, supports continuing current

194 d vaginal pH (87% versus 48%; P < 0.001) and gonorrhea infection (15% versus 4%; P = 0.002).

195 tant role in the pathogenesis of symptomatic gonorrhea infection and that alterations in lipid A bios

196 Those with more than one gonorrhea infection separated by more than 14 days durin

197 Repeat gonorrhea infections are prevalent in Baltimore and like

198 One hundred pharyngeal and 100 rectal gonorrhea infections in 190 men were included.

199 licor CT/NG test) detection of chlamydia and gonorrhea infections in a cross-sectional study of 793 a

200 d intravaginal swabs to detect chlamydia and gonorrhea infections was an accurate diagnostic method f

201 30 (21.8%) and 108/840 (12.9%) chlamydia and gonorrhea infections, respectively, were identified.

202 damage characteristic of whooping cough and gonorrhea infections.

203 matis (chlamydia) and Neisseria gonorrhoeae (gonorrhea) infections in women.

204 Prevention and control of gonorrhea is an important public health concern due to t

205 The hallmark of gonorrhea is an intense inflammatory response that is ch

206 The epidemiology of gonorrhea is characterized by geographically defined hyp

207 Acute gonorrhea is characterized by neutrophilic inflammation

208 city of urine-based assays for chlamydia and gonorrhea is limited, and the possible misclassification

209 A safe and effective vaccine against gonorrhea is needed because of emerging resistance of go

210 Gonorrhea is the second most commonly reported notifiabl

211 eisseria gonorrhoeae, the etiologic agent of gonorrhea, is frequently asymptomatic in women, often le

212 agent of the sexually transmitted infection gonorrhea, is not preventable by vaccination and is rapi

213 Neisseria gonorrhoeae, which causes gonorrhea, is particularly adept at driving HIV-1 expres

214 tested 96 urine samples collected along with Gonorrhea Isolate Surveillance Project (GISP) urethral s

215 stic, the authors analyzed reported cases of gonorrhea (n = 32,454) in Baltimore City, Maryland, from

216 e used in conjunction with routine chlamydia/gonorrhea nucleic acid-based screening are likely to hav

217 were independently associated with anorectal gonorrhea (odds ratios [ORs], 3.3 [95% confidence interv

218 Gonorrhea often occurs as a coinfection with human immun

219 ith Chlamydia only were 65% (20/31) and with gonorrhea only were 73% (33/45).

220 acterial agent targeted for the treatment of gonorrhea, operates by a novel mode-of-inhibition agains

221 However, conjunctivitis caused by gonorrhea or chlamydia and conjunctivitis in contact len

222 Among females with a history of gonorrhea or chlamydia in the previous 12 months, chlamy

223 nts without treatment indications for either gonorrhea or chlamydia: 7% in men and 9% in women (relat

224 primary outcome was persistent or recurrent gonorrhea or chlamydial infection in patients 3 to 19 we

225 Persistent or recurrent gonorrhea or chlamydial infection occurred in 121 of 931

226 mly assigned women and heterosexual men with gonorrhea or chlamydial infection to have their partners

227 Heterosexual individuals with gonorrhea or chlamydial infection were eligible for the

228 reduces the rates of persistent or recurrent gonorrhea or chlamydial infection.

229 Many sex partners of persons with gonorrhea or chlamydial infections are not treated, whic

230 intercourse (OR, 2.98; 95% CL, 1.20-7.45) or gonorrhea (OR, 3.03 95% CI, 1.07-8.63) predicted the pre

231 nal film did not reduce the rate of new HIV, gonorrhea, or chlamydia infection in this group of sex w

232 A positive syphilis, gonorrhea, or chlamydia test was significantly associate

233 ein-Barr virus, human herpesviruses 6 and 8, gonorrhea, or chlamydia.

234 rt study of adults diagnosed with chlamydia, gonorrhea, or syphilis in Kaiser Permanente Southern Cal

235 requency of bacterial vaginosis (P<.001) and gonorrhea (P=.03).

236 ited number of other organisms, including N. gonorrhea, P. aeruginosa, and Synechocystis PCC6803, als

237 es resistant to antimicrobials used to treat gonorrhea, percentage of patients treated with specific

238 then tested 100 urine specimens, known to be gonorrhea positive by nucleic acid amplification testing

239 RT-PCR analysis indicated that gonorrhea-positive specimens where rmp expression was se

240 Overall anorectal chlamydia/gonorrhea positivity was 13.4% (n = 127)/1.3% (n = 12).

241 For pharyngeal gonorrhea, positivity of N. gonorrhoeae DNA on both PCR

242 rrhoeae is implicated in the pathogenesis of gonorrhea, possibly by mediating adherence and entry of

243 ctal screening with respect to chlamydia and gonorrhea prevalence and risk factors.

244 To measure chlamydia and gonorrhea prevalence in the United States.

245 e impact of safe behavior on the dynamics of gonorrhea prevalence.

246 treatment recommendations for chlamydia and gonorrhea; prevention and screening recommendations for

247 sible for the sexually transmitted infection gonorrhea, protects against exogenous induction of apopt

248 tions were found for chlamydia (r=0.577) and gonorrhea (r=0.521).

249 N. gonorrhoeae, while commercially available gonorrhea rapid kit showed a detection limit of 10(6) CF

250 Among patients with gonorrhea, rates of infection with strains with decrease

251 s an independent risk factor for both repeat gonorrhea (relative hazard [RH] = 1.22; 95% confidence i

252 evidence for screening men for chlamydia and gonorrhea remains insufficient at this time, all sexuall

253 Gonorrhea remains one of the most frequent infectious di

254 Gonorrhea reported between 2001 and 2002 was geocoded an

255 y transmitted diseases such as chlamydia and gonorrhea requires systemic treatment in addition to top

256 icemia, and the sexually transmitted disease gonorrhea, respectively.

257 96.3% (26 of 27) and 98.2% (752 of 766) for gonorrhea, respectively.

258 4 was an independent risk factor for repeat gonorrhea (RH = 1.50; 95% CI = 1.12-1.98), and there was

259 ype, as recommended by the CDC for chlamydia/gonorrhea screening among women.

260 the recommended specimen type for chlamydia/gonorrhea screening.

261 omplement contact tracing for reconstructing gonorrhea sexual networks, the concordance between the N

262 temporal trends in syphilis, chlamydia, and gonorrhea testing among sexually active HIV-infected adu

263 To guide interpretation of gonorrhea tests of cure using nucleic acid amplification

264 ight critical questions in the management of gonorrhea that can be addressed by mathematical models a

265 n used successfully in a chimpanzee model of gonorrhea that simulates human disease.

266 For gonorrhea, the rate increased by 57% (94/100,000 vs. 148

267 For gonorrhea, the sensitivity and specificity of dry swabs

268 antimicrobial agents has reduced options for gonorrhea therapy worldwide.

269 utility of this class of antimicrobials for gonorrhea therapy.

270 effects to expect a highly efficacious anti-gonorrhea therapy.

271 herapy with ceftriaxone and azithromycin for gonorrhea to ensure effective treatment and slow emergen

272 An SIS/SAS model of gonorrhea transmission in a population of highly active

273 A mathematical model describing gonorrhea transmission incorporated resistance emergence

274 veloped and analyzed a mathematical model of gonorrhea transmission, incorporating patient flow throu

275 Gonorrhea treatment has been complicated by antimicrobia

276 rol and Prevention guidelines for pharyngeal gonorrhea treatment recommend dual therapy with intramus

277 n resistance has declined in the years since gonorrhea treatment with penicillin was discontinued.

278 d the usefulness of existing antibiotics for gonorrhea treatment, but ongoing monitoring of resistanc

279 e is the foundation of currently recommended gonorrhea treatment.

280 f infection and is a promising new agent for gonorrhea treatment.

281 out of 28) of GC isolated from uncomplicated gonorrhea (UG) patients, pgtA lacked the poly-G.

282 with men diagnosed with pharyngeal or rectal gonorrhea underwent swabbing from the pharynx or rectum

283 Overall prevalence of gonorrhea was 0.43% (95% CI, 0.29%-0.63%).

284 osed among homosexual men was 2.8%, that for gonorrhea was 17.4%, and that for syphilis was 32.1%.

285 Prior infection with gonorrhea was positively associated with risk (odds rati

286 Gonorrhea was reported from 196/202 (97%) of census trac

287 The rates of gonorrhea were 33.3 and 31.1 cases per 100 woman-years i

288 The overall prevalences of gonorrhea were 6.6% in women and 20.1% in men.

289 nce rates for the detection of chlamydia and gonorrhea were 99.7% (kappa = 0.97) and 99.8% (kappa = 0

290 vice use, alcohol consumption, syphilis, and gonorrhea were all significantly associated with the pre

291 A total of 1440 cases of pharyngeal gonorrhea were diagnosed during the study period, 25% of

292 y transmitted disease clinic with urogenital gonorrhea were enrolled.

293 ears diagnosed with uncomplicated urogenital gonorrhea were randomly assigned to either gentamicin 24

294 During those 5 years, 8613 cases of gonorrhea were reported among males and 3893 among femal

295 ual behavior-namely, alcohol consumption and gonorrhea-were each independently associated with HHV-8

296 sseria gonorrhoeae is the etiologic agent of gonorrhea, which has been among the most frequently repo

297 ndings may help to improve animal models for gonorrhea while also having implications in the choice o

298 of 154 women with treatment indications for gonorrhea who would not otherwise have been treated for

299 perform well for detection of chlamydia and gonorrhea with self-obtained vaginal swabs shipped in a

300 herapeutic and prophylactic strategy against gonorrhea, with implications for the development of an e